A 5-Year Plan for Investing in SpaceX Today at $133
Rocket Lab has shed nearly half its value from its 52-week high, and a dense stack of defense contracts and a make-or-break rocket debut are colliding at exactly the moment insiders are heading for the exits.
At $82.83, Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) presents a scale-in research case for investors building a five-year position in the space economy. The stock has pulled back sharply from its $151 52-week high, creating a discounted entry into a name levered to nearly every current defense-space tailwind.
Rocket Lab is the second-largest Western launch provider after SpaceX, with the Electron rocket, the HASTE hypersonic testbed, and a fast-expanding space systems business spanning satellites, solar arrays, laser optical comms, and payloads. A string of acquisitions Mynaric AG, Motiv Space Systems, and the $325M Geost deal has turned it into a vertically integrated prime contractor.
The share price ran from roughly $55 last November to triple-digits earlier this year on defense wins and Neutron progress, then gave back gains this summer.
The Bull Case: A Defense-Space Prime in the Making
Q1 FY2026 was a breakout quarter. Revenue hit $200.35 million, up 63.5% year over year, beating consensus, while non-GAAP gross margin expanded to 43.0% from 33.4%. Backlog swelled to $2.20 billion, and the company signed 31 new Electron/HASTE contracts plus 5 Neutron missions in a single quarter.
The catalyst stack is dense. An $816 million Space Development Agency award for 18 Tranche 3 satellites is the largest in company history. Rocket Lab was picked for the Department of War’s Golden Dome Space Based Interceptor program with Raytheon and for the MDA SHIELD program, worth up to $151 billion. The Neutron medium-lift reusable rocket is on track for a debut launch later this year.
Analyst positioning skews bullish: 14 Buy or Strong Buy ratings versus 3 Holds and zero Sells. Revenue has grown from $62.2 million in 2021 to $601.8 million in 2025.
The Bear Case: Losses, Dilution, and Insider Exits
Rocket Lab is still deeply unprofitable. FY2025 posted a net loss of $198.2 million and free cash flow of negative $321.8 million. R&D jumped to $270.7 million, and stock-based comp hit $71 million for the year. The company raised $450 million via ATM in Q1 alone, diluting holders.
Valuation is aggressive. Price-to-sales sits at 76x, and there is no meaningful P/E because earnings are negative. Neutron has already slipped once after a stage-1 tank test failure. Insiders have been sellers: CEO Peter Beck executed 24 separate disposals across July 6-8, 2026, at prices ranging from $81.59 to $101.57, while the CFO, COO, and General Counsel sold in the $139-$150 range in late May.
The Case for Patience: Wait for Neutron Proof
Neutron is the swing factor. A successful debut unlocks medium-lift revenue, national security launch competition, and constellation deployment economics. A second delay or test failure would reset the narrative. Beta of 2.629 guarantees volatility, and the 35% one-month drawdown shows how quickly enthusiasm can invert.
The Data: Above Consensus, Above the S&P
Shares trade at $82.83 against a Wall Street consensus target of $111.31, implying 34.38% upside across 17 covering analysts. RKLB is up 18.74% year-to-date and 87.36% over the trailing year, well ahead of the S&P 500 over the same stretch. Over five years, the stock is up 615.9%.
The Verdict: A Case for Scaling In
At $82.83, Rocket Lab warrants a closer look. A framework some investors consider involves a 30% to 50% starter position at $133 to $135, with reserve capital added on macro pullbacks toward a $110 to $115 support floor. Shares have already fallen well below both bands, strengthening the case for accumulation.
The path to appreciation is Neutron’s debut, execution against the $2.20 billion backlog, and continued capture of Golden Dome and SHIELD dollars. The thesis breaks if Neutron fails a second time, if margin expansion reverses, or if dilution outpaces revenue growth. Insider selling is a yellow flag; CEO Beck’s July disposals deserve monitoring on the next 13F cycle.
Watch Neutron milestones, gross margin durability above 40%, and backlog conversion into recognized revenue. The cost of waiting for perfect clarity is missing a rerating tied to Neutron success.
A tranche-based approach at these levels would offer exposure to the defense-space cycle without concentrating risk on a single launch outcome.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
